论文部分内容阅读
目的 观察胸腺肽α1在恶性肿瘤治疗中的价值。方法 15例胸腺肽α1治疗组 :胸腺肽α1用法为 1.6mg/次 ,皮下注射 ,每周 2次 ,中位疗程为 3.5个月。以外周血T淋巴细胞核仁形成区嗜银蛋白 (Ag NORs)含量 (I .S %值 )作为为评价机体免疫功能状况的指标。对照组 :15例正常人。未治疗组 :15例恶性肿瘤但未接受胸腺肽α1治疗患者 ;对其45例外周血T淋巴细胞Ag NORs含量进行检测 ,并对治疗组应用胸腺肽α1前后的Ag NORs含量进行动态观察。结果 正常人外周血T淋巴细胞Ag NORs含量显著高于治疗组和未治疗组患者 (P <0 .0 1) ,而治疗组与未治疗组间无显著差异(P >0 .0 5 ) ;治疗组患者应用胸腺肽α1后Ag NORs含量较用药前明显提高 (P <0 .0 5 )。结论 恶性肿瘤患者存在明显的免疫功能下降 ,应用胸腺肽α1可调节和提高肿瘤患者的细胞免疫功能。
Objective To observe the value of thymosin α1 in the treatment of malignant tumors. Methods 15 cases of thymosin α1 treatment group: thymosin α1 usage of 1.6mg / subcutaneous injection twice a week, the median course of 3.5 months. Peripheral blood T-lymphocyte nucleolar organizer region AgNOS content (I .S% value) as an index to evaluate the body’s immune function status. Control group: 15 normal people. Untreated group: 15 cases of malignant tumor but not treated with thymosin α1; 45 cases of peripheral blood T lymphocytes AgNORs were detected, and the treatment group before and after the application of thymosin α1 Ag NORs dynamic observation. Results The levels of AgNORs in peripheral blood T lymphocytes in normal subjects were significantly higher than those in the untreated and untreated groups (P <0.01), while there was no significant difference between the untreated and untreated groups (P> 0.05). In the treatment group, the content of Ag NORs after thymosin α1 administration was significantly higher than that before treatment (P <0.05). Conclusion There is a significant decrease in immune function in patients with malignant tumors. Thymosin α1 can regulate and enhance the cellular immune function in cancer patients.